Clinical trials: Fibrolamellar Carcinoma
- Condition Fibrolamellar Carcinoma
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Melanoma, Hodgkin Lymphoma
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors.
- Conditions
- Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma, Glioblastoma Multiforme (GBM)
- Trial name
- NCT06521567
- Testing
- Cobolimab, Dostarlimab
- Where
- 20 sites in United States, Czechia and 4 more
- Volunteers
- 83 people
- Sponsor
- GlaxoSmithKline
Advanced Adult Hepatocellular Carcinoma, Advanced Fibrolamellar Carcinoma
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma
The purpose of the study is to determine whether once-daily dosing with ENMD-2076 will be a safe and effective treatment in patients with FLC.
- Trial name
- NCT02234986
- Testing
- ENMD-2076
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- CASI pharmaceuticals, Inc.